Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Q-Line Biotech's selling, general, & admin. expense for the
six
months ended in Mar. 2025 was ₹215 Mil.
Q-Line Biotech does not have enough years/quarters to calculate its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2025.
Q-Line Biotech (NSE:QLINE) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Q-Line Biotech Selling, General, & Admin. Expense Related Terms
Q-Line Biotech Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Selling, General, & Admin. Expense Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Selling, General, & Admin. Expense
172.77
176.17
215.29
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Selling, General, & Admin. Expense
172.77
176.17
215.29
NSE:QLINE vs ABT, SYK, MDT: Selling, General, & Admin. Expense Comparison
For the Medical Devices subindustry, Q-Line Biotech's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Selling, General, & Admin. Expense falls into.
Q-Line Biotech Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
What does a Selling, General, & Admin. Expense of ₹ Mil mean?
Q-Line Biotech (NSE:QLINE) has a Selling, General, & Admin. Expense of ₹ Mil as of Mar. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Selling, General, & Admin. Expense too high?
Q-Line Biotech's current Selling, General, & Admin. Expense is ₹ Mil. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Selling, General, & Admin. Expense compare to ABT and SYK?
Q-Line Biotech's Selling, General, & Admin. Expense of ₹ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Selling, General, & Admin. Expense is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Selling, General, & Admin. Expense of ₹ Mil. The current Selling, General, & Admin. Expense is ₹ Mil. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Selling, General, & Admin. Expense is ₹ Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score
Get the complete analysis for NSE:QLINE
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 
